Chronic mucocutaneous candidiasis (CMC) is characterized by persistent or recurrent disease of the nails, skin, oral, or genital mucosae caused by *Candida albicans* ([@bib59]). CMC may be caused by various inborn errors of immunity. CMC is one of a multitude of infectious diseases observed in patients with broad and profound T cell deficiencies. In contrast, patients with the autosomal dominant (AD) hyper IgE syndrome, caused by dominant-negative mutations of *STAT3*, are susceptible principally to CMC and staphylococcal diseases of the lungs and skin ([@bib53]). These patients have very low proportions of circulating IL-17A-- and IL-22--producing T cells, probably because of impaired responses to IL-6, IL-21, and/or IL-23 ([@bib20]; [@bib49]; [@bib52]; [@bib62]; [@bib54]). Patients with autosomal recessive (AR) IL-12p40 or IL-12Rβ1 deficiency suffer from Mendelian susceptibility to mycobacterial disease (MSMD) and occasionally develop mild CMC ([@bib30]; [@bib21]). Some have low proportions of IL-17A-- and IL-22--producing T cells, presumably because of the abolition of IL-23 responses ([@bib20], [@bib21]). The proportion of IL-17A--producing T cells was also found to be low in a family with AR CARD9 deficiency, dermatophytosis, invasive candidiasis, and CMC ([@bib32]). Finally, CMC is the only infection in patients with autoimmune polyendocrinopathy syndrome type 1, who have high titers of neutralizing autoantibodies against IL-17A, IL-17F, and IL-22 ([@bib41]; [@bib58]). Thus, regardless of the underlying illness, CMC pathogenesis apparently involves the impairment of IL-17A, IL-17F, and IL-22 immunity ([@bib59]).

The pathogenesis of CMC was eventually deciphered through investigations of patients with CMC disease (CMCD), in which CMC is isolated, with no other infectious or autoimmune signs ([@bib40]; [@bib59]). The definition of CMCD is not absolute, as illustrated in some patients by cutaneous staphylococcal disease, which is milder than that in patients with AD hyper IgE syndrome ([@bib34]), or by autoimmune features affecting the thyroid in particular, although fewer such features are observed than in patients with autoimmune polyendocrinopathy syndrome type 1 ([@bib5]). It is unclear whether CMCD, with these or other manifestations ([@bib65]; [@bib8]; [@bib31]), is immunologically and genetically related to pure CMCD. Low proportions of IL-17A--producing T cells have been documented in five patients with CMCD ([@bib27]). Moreover, a candidate gene approach centered on IL-17 immunity recently revealed the first genetic etiologies of pure CMCD. In a consanguineous family from Morocco, a child with CMCD was found to display AR complete IL-17RA deficiency ([@bib60]). His leukocytes and fibroblasts did not respond to IL-17A or IL-17F homodimers, or to IL-17A/F heterodimers. Four patients from an Argentinean family were shown to harbor dominant-negative mutations in the *IL17F* gene ([@bib60]). Mutated IL-17F--containing homodimers and heterodimers were produced in normal amounts but were not biologically active, as they were unable to bind to the IL-17 receptor. Morbid mutations in *IL17RA* and *IL17F* demonstrated that CMCD could be caused by inborn errors of IL-17 immunity. However, no genetic etiology has yet been identified for most patients with CMCD. We set out to identify new genetic etiologies of CMCD through a recently developed genome-wide approach based on whole-exome sequencing ([@bib3]; [@bib9]; [@bib11]; [@bib55]).

RESULTS
=======

We investigated one sporadic case and the probands from five multiplex kindreds with AD CMCD, by whole-exome sequencing. The annotated data were analyzed with sequence analysis software that had been developed in-house and made it possible to analyze and compare several exome sequences simultaneously. A hierarchy of candidate variations was generated by filtering out known polymorphisms reported in dbSNP and 1,000-genome databases. We also used our own database of 250 exomes to filter out unreported polymorphisms ([Table S1](http://www.jem.org/cgi/content/full/jem.20110958/DC1)). The only relevant gene displaying heterozygous variations in at least four of the six unrelated patients with AD CMCD was *STAT1* ([Fig. 1, A and B](#fig1){ref-type="fig"}, Kindreds A, B, G, and L; [Table I](#tbl1){ref-type="table"}; and [Table S2](http://www.jem.org/cgi/content/full/jem.20110958/DC1)). Three different *STAT1* mutations were found in four patients; they were confirmed by Sanger sequencing and shown to be missense mutations. All these mutations affected the coiled-coil domain, which plays a key role in unphosphorylated STAT1 dimerization and STAT1 nuclear dephosphorylation ([Fig. 1, A and C](#fig1){ref-type="fig"}; [@bib17]; [@bib45]; [@bib10]; [@bib71]; [@bib36]; [@bib51]). We therefore sequenced the corresponding coding region of *STAT1* (exons 6 to 10) in another 106 patients, including 57 with sporadic CMCD and 49 from 22 multiplex kindreds with AD CMCD. 29 patients from 16 kindreds were heterozygous for a *STAT1* missense mutation ([Fig. 1, A and B](#fig1){ref-type="fig"}, Kindreds C-F, H-K, and M-T; [Fig. 1 C](#fig1){ref-type="fig"}; and [Table I](#tbl1){ref-type="table"}; [Table S3](http://www.jem.org/cgi/content/full/jem.20110958/DC1)). In total, 36 patients from 20 kindreds were heterozygous for 1 of the 12 missense mutations identified that affected the coiled-coil domain of STAT1. 11 other CMCD patients in these kindreds were not genotyped. The intrafamilial segregation of the mutations was consistent with an AD trait, as all patients with CMCD from the kindreds tested were heterozygous, whereas none of these mutations was found in the heterozygous state in any of the healthy relatives tested ([Fig. 1 B](#fig1){ref-type="fig"}). Moreover, the *STAT1* haplotypes for common SNPs indicated that the five recurrent mutations were caused by mutation hotspots rather than founder effects (unpublished data). Finally, the mutations were found to have occurred de novo in at least four kindreds, which is consistent with a high clinical penetrance of these alleles. The mutations were not found in the National Center for Biotechnology Information, Ensembl, and dbSNP databases. They were also absent from 1,052 controls from 52 ethnic groups in the Centre d'Etude du Polymorphisme Humain and Human Genome Diversity panels, suggesting that they were rare, CMCD-inducing variants rather than irrelevant polymorphisms.

###### 

Summary of the clinical and genetic data for the patients

  Patient   Age at presentation   Origin           Clinical features of CMC                               Cause of death (age/yr)                Autoimmunity                   Genotype
  --------- --------------------- ---------------- ------------------------------------------------------ -------------------------------------- ------------------------------ ----------
  A-I-1     \-                    France           Nails                                                  Not related to the disease (old age)   None                           \-
  A-II-1    \-                    France           Nails                                                  Not related to the disease (old age)   None                           \-
  A-III-1   1 mo                  France           Nails, oral cavity, oropharynx, genital mucosa                                                None                           WT/R274Q
  A-III-3   \-                    France           Nails, oral cavity                                     Not related to the disease (40)        None                           \-
  A-III-4   \-                    France           Nails, oral cavity                                                                            None                           \-
  A-IV-1    1 mo                  France           Nails, oral cavity, oropharynx                                                                None                           WT/R274Q
  B-II-1    \-                    France           \-                                                                                            None                           \-
  B-III-2   3 yr                  France           Skin, nails, oral cavity, oropharynx, genital mucosa                                          None                           WT/K286I
  B-IV-1    5 yr                  France & Congo   Skin, nails, oral cavity, oropharynx                                                          None                           WT/K286I
  B-IV-2    5 mo                  France & Congo   Skin, nails, oral cavity, oropharynx                   Cerebral aneurysm (8)                  None                           \-
  C-III-1   \-                    Turkey           Nails, oral cavity, genital mucosa                     Cerebral aneurysm (34)                 Thyroid autoimmunity           WT/R274Q
  C-IV-1    \-                    Turkey           Nails, oral cavity                                                                            None                           WT/R274Q
  D-II-1    \-                    France           Nails, oral cavity, genital mucosa                                                            \-                             \-
  D-III-2   7 yr                  France           Skin, oral cavity, oropharynx                                                                 None                           WT/M202V
  D-IV-2    1 mo                  France           Skin, nails, oropharynx                                                                       Thyroid autoimmunity           WT/M202V
  E-II-1    1 yr                  Germany          Skin, oral cavity, oropharynx                          Squamous cell carcinoma (54)           \-                             \-
  E-III-2   1 yr                  Germany          Nails, oral cavity, oropharynx, genital mucosa                                                Thyroid autoimmunity           WT/C174R
  E-III-3   9 mo                  Germany          Skin, nails, oral cavity, oropharynx, genital mucosa                                          Thyroid autoimmunity           WT/C174R
  E-IV-1    18 mo                 Germany          Skin, oral cavity, oropharynx, genital mucosa                                                 None                           WT/C174R
  E-IV-2    2 yr                  Germany          Skin, oral cavity, oropharynx                                                                 Thyroid autoimmunity           WT/C174R
  E-IV-4    2 yr                  Germany          Skin, oral cavity, oropharynx, genital mucosa                                                 None                           WT/C174R
  E-IV-5    1 yr                  Germany          Skin, nails, oral cavity, oropharynx                                                          None                           WT/C174R
  F-III-2   1 mo                  Argentina        Nails, oral cavity, oropharynx, genital mucosa                                                \-                             WT/R274W
  F-IV-2    1 mo                  Argentina        Skin, nails, oral cavity, oropharynx                                                          \-                             WT/R274W
  F-IV-3    6 mo                  Argentina        Nails, oral cavity, genital mucosa                                                            \-                             WT/R274W
  G-II-1    3 mo                  Ukrainian        Nails, skin, oral cavity, oropharynx, esophagus                                               None                           WT/D165G
  H-I-2     1 yr                  Japan            Skin, oropharynx, esophagus                                                                   \-                             WT/R274Q
  H-II-2    5 yr                  Japan            Oral cavity, oropharynx                                                                       \-                             WT/R274Q
  I-II-3    9 mo                  Mexico           Skin, nails, oral cavity, genital mucosa                                                      None                           WT/T288A
  J-I-2     \-                    Switzerland      Oral cavity, oropharynx                                                                       None                           WT/T288A
  J-II-2    3 mo                  Switzerland      Oral cavity, oropharynx                                                                       \-                             WT/T288A
  K-II-2    11 mo                 Switzerland      Nails, oral cavity, oropharynx                                                                Thyroid autoimmunity           WT/Y170N
  L-I-2     7 yr                  France           Skin, nails, oropharynx, esophagus                                                            Thyroid autoimmunity           WT/R274Q
  L-II-1    1 mo                  France           Skin, nails, oropharynx, esophagus                                                            None                           WT/R274Q
  M-II-2    6 mo                  Germany          Skin, nails, oropharynx, genital mucosa                                                       Thyroid autoimmunity           WT/D165H
  N-II-2    1 yr                  Germany          Skin, nails, oropharynx                                Squamous cell carcinoma (54)           None                           WT/R274W
  O-II-1    18 mo                 Germany          Oral cavity, oropharynx                                                                       None                           WT/M202I
  P-I-1     1 yr                  Israel           Oropharynx, genital mucosa                             Not related to the disease (46)        None                           \-
  P-II-1    \<2 yr                Israel           Skin, nails, oropharynx                                                                       None                           WT/A267V
  P-II-2    \<2 yr                Israel           Skin, nails, oropharynx                                                                       None                           WT/A267V
  Q-II-1    1 mo                  France           Skin, oral cavity, oropharynx, genital mucosa                                                 None                           WT/R274W
  R-I-1     4 yr                  France           Skin, nails, oropharynx                                Squamous cell carcinoma (55)           None                           \-
  R-II-1    18 mo                 France           Lips, oropharynx                                                                              None                           WT/M202V
  S-I-2     6 mo                  France           Skin, oral cavity, oropharynx                                                                 Systemic lupus erythematosus   WT/M202I
  S-II-2    1 yr                  France           Nails                                                                                         None                           \-
  S-II-3    1 mo                  France           Skin, oropharynx                                                                              None                           WT/M202I
  T-II-3    1 yr                  Germany          Skin, nails, oropharynx                                Squamous cell carcinoma (41)           None                           WT/Q271P

None of the patients displays autoantibodies against IL-17A, IL-17F, and IL-22. -, unknown

![**Heterozygous missense mutations affecting the STAT1 coiled-coil domain in kindreds with AD CMCD.** (A) The human *STAT1* α isoform is shown, with its known pathogenic mutations. Coding exons are numbered with roman numerals and delimited by a vertical bar. Regions corresponding to the coiled-coil domain (CC), DNA-binding domain (DNA-B), linker domain (L), SH2 domain (SH2), tail segment domain (TS), and transactivator domain (TA) are indicated, together with their amino-acid boundaries, and are delimited by bold lines. Tyr701 (pY) and Ser727 (pS) are indicated. Mutations in green are dominant and associated with partial STAT1 deficiency and MSMD. Mutations in brown are recessive and associated with complete STAT1 deficiency and intracellular bacterial and viral disease. Mutations in blue are recessive and associated with partial STAT1 deficiency and intracellular bacterial and/or viral disease. Mutations in red are dominant and associated with a gain-of-function of STAT1 and CMCD. (B) Pedigrees of 20 families with AD "gain-of-function" *STAT1* mutations. Each kindred is designated by a letter (A to T), each generation is designated by a roman numeral (I-II-III-IV), and each individual is designated by an Arabic numeral (each individual studied is identified by a code of this type, organized from left to right). Black indicates CMCD patients. The probands are indicated by arrows. When tested, the genotype for *STAT1* is indicated below each individual. (C) Three-dimensional structure of phosphorylated STAT1 in complex with DNA. Connolly surface representation, with the following amino acids highlighted: red, amino acids mutated in patients with CMCD; blue, amino acids located in the coiled-coil domain and mutated in patients with MSMD and viral diseases; yellow, amino acids identified in vitro as affecting the dephosphorylation process.](JEM_20110958_RGB_Fig1){#fig1}

The 12 missense mutations were not conservative and were therefore predicted to affect protein structure and function. Moreover, most of the affected residues were found to have been conserved throughout evolution in the species in which *STAT1* had been sequenced (Table S3). Accordingly, POLYphen II predicted that all but one of these mutations would be possibly or probably damaging ([@bib1]; Table S3). None of the previously described nine patients with AD STAT1 deficiency and MSMD was heterozygous for mutations affecting the coiled-coil domain ([Fig. 1, A and C](#fig1){ref-type="fig"}; [@bib24]; [@bib14]; [@bib6]; unpublished data). However, three of the eight patients with AR STAT1 deficiency and susceptibility to intracellular bacterial and viral diseases, who, like their heterozygous relatives, did not display CMC, carried mutations affecting the coiled-coil domain ([Fig. 1, A and C](#fig1){ref-type="fig"}; [@bib16]; [@bib15]; [@bib25]; [@bib43]; [@bib44]; [@bib6]). These three patients from two kindreds carried the K201N or K211R mutation ([@bib43]; [@bib44]). Nevertheless, the three-dimensional structure of phosphorylated STAT1 molecules revealed that the 12 CMCD-linked missense mutations affected a cluster of residues located in a specific pocket of the coiled-coil domain, near residues essential for STAT1 dephosphorylation ([Fig. 1 C](#fig1){ref-type="fig"}; [@bib17]; [@bib71]; [@bib51]). In contrast, the other two morbid mutations (K201N and K211R) affect residues located on the other side of the coiled-coil domain ([Fig. 1 C](#fig1){ref-type="fig"}). Moreover, these two hypomorphic alleles were shown to be pathogenic not because they were missense, but because they promoted the splicing out of exon 8, resulting in AR partial STAT1 deficiency, with the production of small amounts of intrinsically functional STAT1 molecules ([@bib43]; [@bib44]). These genetic data strongly suggest that heterozygous missense mutations in the coiled-coil domain of STAT1 may cause AD CMCD in a large fraction of patients. Nevertheless, the occurrence of other germline mutations in *STAT1* in patients without CMC and with an AD or AR predisposition to other infectious diseases raised questions about whether these mutations were really responsible for CMCD and the underlying mechanism of disease.

We functionally characterized the CMCD-causing *STAT1* allele R274Q, which was found in four kindreds ([Fig. 1 B](#fig1){ref-type="fig"} and [Table I](#tbl1){ref-type="table"}). We compared it with a WT and an MSMD-causing loss-of-function *STAT1* allele (L706S; [@bib24]). We transfected STAT1-deficient U3C fibrosarcoma cells with WT, R274Q, or L706S *STAT1* alleles. Upon stimulation with IFN-α, IFN-γ, or IL-27, cells transfected with the R274Q allele responded two to three times more strongly than those transfected with the WT allele, as shown by measurement of the induction of γ-activated sequence (GAS)--dependent reporter gene transcription activity, with mock- and L706S-transfected cells serving as negative controls ([Fig. 2 A](#fig2){ref-type="fig"} and [Fig. S1 A](http://www.jem.org/cgi/content/full/jem.20110958/DC1)). All *STAT1* alleles were expressed at an equal strength, as shown by Western blotting (WB; [Fig. 2 B](#fig2){ref-type="fig"}). Higher levels of STAT1 phosphorylation were observed for the R274Q allele than for the WT allele after stimulation with IFN-γ, IFN-α, and IL-27, whereas STAT3 phosphorylation levels were similar for the two alleles ([Fig. 2 B](#fig2){ref-type="fig"}). In contrast, the induction of IFN-stimulated response element (ISRE)--dependent transcription activity by IFN-α was normal (Fig. S1, B and C). In the same experimental conditions, the other 10 CMCD-associated *STAT1* alleles tested were also gain-of-function, unlike the K201N and K211R alleles (Fig. S1 D). Upon stimulation with IFN-γ, IFN-α, or IL-27, an increase in GAS-binding activity was detected in cells transfected with the R274Q allele (Fig. S1 E). Accordingly, the transcription of the *CXCL9* and *CXCL10* target genes was enhanced ([Fig. 2, C and D](#fig2){ref-type="fig"}). Overall, these data indicate that at least 11 of the 12 CMCD-linked *STAT1* missense alleles are intrinsically gain-of-function.

![**The mutant R274Q *STAT1* allele is gain-of-phosphorylation and gain-of-function for GAF-dependent cellular responses.** U3C cells were transfected with a mock vector, a WT, or two mutant alleles of *STAT1* (R274Q and L706S). The response to IFN-γ, IL-27, and IFN-α was then evaluated by determining luciferase activity of a reporter gene under the control of the GAS promoter (A), and by determining STAT1 and STAT3 phosphorylation by Western blot (B). Experiments were performed at least three times independently. (C and D) Quantitative RT-PCR was used to measure the induction of *CXCL9* (C) and *CXCL10* (D) 2--8 h after stimulation with IFN-γ. Experiments were performed two times independently. (E) The nuclear dephosphorylation of STAT1 was tested by WB in U3C cells transfected with a mock vector, WT *STAT1*, the R274Q, or the F77A (a known loss-of-dephosphorylation mutant) *STAT1* mutant alleles, and treated with IFN-γ with or without the tyrosine kinase inhibitor staurosporine for the indicated periods of time (in minutes). Three independent experiments were performed. (F) Western blot of U3C cells transfected with mock, WT, R274Q, D165G, and F77A alleles of *STAT1,* nontreated or treated with IFN-γ in the absence or presence of the phosphatase inhibitor pervanadate. Two independent experiments were performed. Error bars represent SD of one experiment done in triplicate (Fig. S1 D).](JEM_20110958_GS_Fig2){#fig2}

The mechanism involved an increase in STAT1 tyrosine 701 residue phosphorylation, as shown for R274Q by WB after stimulation with IFN-α, IFN-γ, and IL-27 ([Fig. 2 B](#fig2){ref-type="fig"}). STAT1 was not constitutively activated, and STAT3 was normally activated in R274Q-transfected cells ([Fig. 2 B](#fig2){ref-type="fig"} and not depicted). Almost all the mutant STAT1 molecules, which were phosphorylated in response to IFN-γ, translocated to and accumulated in the nucleus, as shown by immunofluorescence (Fig. S1 F). WB showed R274Q STAT1 to be more strongly phosphorylated than the WT protein in both cytoplasmic and nuclear extracts (Fig. S1 G). The mechanism underlying the gain of R274Q phosphorylation was explored with the tyrosine kinase inhibitor staurosporine and the phosphatase inhibitor pervanadate. The dephosphorylation of IFN-γ--activated R274Q STAT1 was impaired by staurosporine, but less than that of the known dephosphorylation mutant F77A ([Fig. 2 E](#fig2){ref-type="fig"}; [@bib71]). In contrast, pervanadate normalized the phosphorylation of R274Q to WT levels ([Fig. 2 F](#fig2){ref-type="fig"}). Another CMCD-linked mutation, D165G ([Fig. 1, A--C](#fig1){ref-type="fig"}), also resulted in impaired dephosphorylation that could be normalized by adding pervanadate ([Fig. 2 F](#fig2){ref-type="fig"} and Fig. S1 H). Thus, at least two CMCD-linked *STAT1* missense alleles (R274Q and D165G) are gain-of-function caused by the impairment of nuclear dephosphorylation. These alleles may therefore enhance cellular responses to cytokines activating STAT1 predominantly and STAT3 to a lesser extent, such as IFN-α/β, IFN-γ, IFN-λ, and IL-27, and possibly also responses to cytokines activating STAT3 predominantly and STAT1 to a lesser extent, such as IL-6, IL-21, IL-22, and IL-23 ([Fig. S2](http://www.jem.org/cgi/content/full/jem.20110958/DC1)).

We investigated the dominance of the *STAT1* alleles at the cellular level by testing EBV-B--transformed (EBV-B) cells and SV-40--transformed dermal fibroblasts from a CMCD patient heterozygous for the *STAT1* R274Q allele. We observed enhanced IFN-α/β--, IFN-γ--, and IL-27--dependent STAT1 phosphorylation in EBV-B cells from a patient heterozygous for the *STAT1* R274Q allele, as shown by WB ([Fig. 3, B and D](#fig3){ref-type="fig"}). Phospho-STAT1 accumulated in the nucleus of R274Q heterozygous SV-40 fibroblasts upon IFN-γ stimulation, as well as in EBV-B cells ([Fig. 3 I](#fig3){ref-type="fig"} and Fig. S3 D). Moreover, the IFN-α/β--, IFN-γ--, and IL-27--induced DNA-binding activity of GAF was stronger in cells from the CMCD patient than in those from a healthy control or from a MSMD patient carrying the L706S mutant allele, as shown by electrophoretic mobility shift assay (EMSA; [Fig. 3, A and C](#fig3){ref-type="fig"}). In contrast, the DNA-binding activity of ISGF-3 seemed to be normal in cells from the patient stimulated with IFN-α/β (Fig. S3 A). These data strongly suggest that the heterozygous R274Q allele is dominant for STAT1-dependent responses and gain-of-function for GAF-dependent cellular responses to key STAT1-activating cytokines, such as IFN-α/β, IFN-γ, and IL-27. The mutation may also affect IFN-λ responses.

![**The mutant R274Q *STAT1* allele is dominant for GAF-dependent cellular responses at the cellular level.** The responses of the patient's EBV-B cells (R274Q/WT) were evaluated independently at least twice, by EMSA, with a GAS probe (A, C, E, and G), and by Western blot (B, D, F, and H). This response was compared with that of one or two healthy controls (WT/WT1 and WT/WT2), heterozygous cells with a WT and a loss-of-function *STAT1* allele (STAT1^+/−^), cells heterozygous for a dominant loss-of-function mutation of *STAT1* (L706S/WT), cells with complete STAT1 deficiency (STAT1^−/−^), and cells from two patients heterozygous for dominant loss-of-function mutations of *STAT3* (STAT3^+/−1^ and STAT3^+/−2^). Cells were left nonstimulated (NS) or stimulated, as indicated, with IFN-γ, IFN-α, IL-27, IL-6, and IL-21. pSTAT is an antibody specific for STAT with a phosphorylated tyrosine residue. (I) The nuclear and cytoplasmic fractions of EBV-B cells from a control (WT/WT), a CMCD patient (R274Q/WT), a heterozygous patient with a dominant loss-of-function mutation of *STAT1* (L706S/WT) and a patient with complete STAT1 deficiency (^−/−^) stimulated with IFN-γ and IFN-α were tested for the presence of phosphorylated STAT1 and STAT1 by WB. Antibodies directed against GAPDH and Lamin B1 were used to normalize the amount of cytoplasmic and nuclear proteins, respectively. The experiment was performed twice.](JEM_20110958_GS_Fig3){#fig3}

We then tested cytokines that predominantly activate STAT3, rather than STAT1, such as IL-6, IL-21, IL-22, and IL-23 ([@bib37]; [@bib42]; [@bib38]; [@bib66]; [@bib23]; [@bib63]; [@bib57]). Peripheral T cell blasts from a patient displayed normal STAT3 activation in response to IL-23, as shown by WB (Fig. S3 B). No increase in STAT1 phosphorylation was detected in cells from a patient or controls upon IL-23 stimulation. Furthermore, fibroblasts from a patient displayed normal activation of STAT3 in response to IL-22 (Fig. S3 C). In the same conditions, no STAT1 phosphorylation was detected in cells from the patient or controls (unpublished data). In contrast, the levels of STAT1 phosphorylation in response to IL-6 and IL-21 were higher in the patient's EBV-B cells than in cells from healthy controls and from a patient with MSMD heterozygous for the L706S allele, whereas STAT3 activation was normal as shown by WB ([Fig. 3, F and H](#fig3){ref-type="fig"}). Consistent with these findings, stronger GAS activity was observed in cells from the patient in response to IL-6 and IL-21 stimulation ([Fig. 3, E and G](#fig3){ref-type="fig"}). These data suggest that heterozygous missense mutations in the coiled-coil domain of STAT1 are dominant and gain-of-function for GAF-dependent cellular responses for cytokines that predominantly activate STAT3, such as IL-6 and IL-21. Overall, these data suggest that the *STAT1* alleles are truly responsible for CMCD in these kindreds and raise questions about the immunological basis of CMCD.

IL-27 is a potent inhibitor of the development of IL-17--producing T cells in mice ([@bib7]; [@bib67]; [@bib70]; [@bib4]; [@bib22]; [@bib26]; [@bib69]) and humans ([@bib22]; [@bib48]), through a mechanism dependent on STAT1 ([@bib4]; [@bib7]; [@bib22]; [@bib48]; [@bib67]; [@bib69]). Moreover, mouse IFN-γ ([@bib29]; [@bib68]; [@bib69]) and human IFN-α/β ([@bib18]; [@bib61]) have been shown to antagonize the development of IL-17--producing T cells via STAT1. In addition, IL-6, IL-21, and IL-23 are prominent inducers of IL-17--producing T cells, via a mechanism dependent on STAT3 and antagonized by STAT1 ([@bib35]). Finally, we recently showed that inborn errors of IL-17F or IL-17RA were genetic etiologies of CMCD ([@bib59], Puel et al., b2011). We thus determined the proportion of IL-17A-- and IL-22--producing T cells by flow cytometry in patients with heterozygous *STAT1* mutations and AD CMCD. The 18 CMCD patients carrying gain-of-function mutations in *STAT1* that were tested had lower proportions of circulating IL-17A-- and IL-22--producing T cells ex vivo than 28 healthy controls (P \< 10^−4^) and six patients bearing loss-of-function *STAT1* alleles (P \< 2.10^−3^; [Fig. 4, A and B](#fig4){ref-type="fig"}; and Fig. S4 G). In contrast, they displayed normal proportions of IFN-γ--producing T cells (Fig. S4 F). Moreover, only very small amounts of IL-17A, IL-17F, and IL-22 were secreted by freshly prepared leukocytes after ex vivo stimulation with PMA and ionomycin (P \< 8.10^−3^), as shown by ELISA ([Fig. 4, C--E](#fig4){ref-type="fig"}). In contrast, the amounts of secreted IL-17A, IL-17F, and IL-22 were normal in patients heterozygous or homozygous for loss-of-function or hypomorphic *STAT1* mutations ([Fig. 4, C--E](#fig4){ref-type="fig"}). Interestingly, in all assays, the proportions of IL-17A-- and IL-22--producing T cells and the amounts of IL-17A, IL-17F, and IL-22 secreted were smallest for the four patients with the most apparently severe clinical phenotype ([Fig. 4, A--E](#fig4){ref-type="fig"} and not depicted).

![**Impaired development and function of IL-17-- and IL-22--producing T cells ex vivo in patients with AD CMCD and *STAT1* mutations.** Each symbol represents a value from a healthy control individual (black circles), a patient bearing a *STAT1* gain-of-function (GOF) allele (red upright triangles), or a patient bearing one or two *STAT1* loss-of-function (LOF) alleles (black upside-down triangles). (A and B) Percentage of CD3^+^/IL-17A^+^ (A) and CD3^+^/IL-22^+^ (B) cells, as determined by flow cytometry, in nonadherent PBMCs activated by incubation for 12 h with PMA and ionomycin. (C--E) Secretion of IL-17F (C), IL-17A (D) and IL-22 (E) by whole blood cells, as determined by ELISA, in the absence of stimulation (open symbols) and after stimulation with PMA and ionomycin for 48 h (closed symbols). Horizontal bars represent medians. The p-values for the nonparametric Wilcoxon test, between patients with *STAT1* GOF mutations (*n* = 18) and controls (*n* = 28) and patients with *STAT1* LOF mutations (*n* = 6) are indicated. All differences between healthy controls and patients with *STAT1* LOF alleles were not significant. (F) Secretion of IL-12p70 by whole blood cells, as determined by ELISA, in the absence of stimulation (open symbols), after stimulation with BCG (lightly colored symbols), or BCG + IFN-γ for 48 h (closed symbols). Horizontal bars represent medians. The p-values for differences between patients with *STAT1* GOF mutations (*n* = 15) and controls (*n* = 23) and patients with *STAT1* LOF mutations (*n* = 6) are indicated and were calculated in nonparametric Wilcoxon tests. All experiments were performed at least two times independently.](JEM_20110958R_RGB_Fig4){#fig4}

After the culture of PBMCs in vitro in the presence of various cytokines, including IL-6, TGF-β, IL-1β, and IL-23, the proportion of IL-17A-- and IL-22--producing T cell blasts remained significantly lower (P \< 10^−4^) in CMCD patients carrying *STAT1* mutations than in controls (Fig. S4, A and B; and not depicted). In contrast, the proportions of IL-17A-- and IL-22--producing T cell blasts were normal in patients with loss-of-function *STAT1* mutations (Fig. S4, A and B; and not depicted). The amounts of IL-17A, IL-17F, and IL-22 in the supernatant of T cell blasts stimulated with PMA and ionomycin after culture in vitro were also significantly lower in patients with *STAT1* mutations and CMCD (P \< 4.10^−4^; Fig. S4, C--E; and not depicted). In contrast, patients with loss-of-function mutant *STAT1* alleles displayed normal levels of cytokine secretion (Fig. S4, C--E; and not depicted). Finally, levels of IL-12p70 and IL-12p40 production by whole blood stimulated with IFN-γ were higher in CMCD patients bearing gain-of-function *STAT1* alleles than in patients bearing loss-of-function *STAT1* alleles and healthy controls ([Fig. 4 F](#fig4){ref-type="fig"} and not depicted). Thus, patients with familial or sporadic AD CMCD heterozygous for mutations affecting the coiled-coil domain of STAT1, including the dominant gain-of-function R274Q mutant allele, displayed lower levels of IL-17 cytokine production by peripheral T cells, providing a molecular mechanism for the disease.

DISCUSSION
==========

We have shown that several germline missense mutations affecting the coiled-coil domain of STAT1 may cause sporadic and familial AD CMCD. The underlying mechanism involves a gain of STAT1 phosphorylation caused by the loss of nuclear dephosphorylation, resulting in a gain-of-function of GAF in response to various cytokines. Impaired dephosphorylation may not be the only mechanism influencing the impact of these mutations on the transcription of STAT1 target genes, as these mutations may also affect other processes, such as the dimerization of unphosphorylated STAT1. Moreover, the gain-of-function, which manifests itself in terms of DNA-binding activity, reporter gene induction, and target gene induction, may not necessarily increase the transcription of all target genes, possibly even resulting in the repression of some genes. In addition, the various *STAT1* mutations, although they all affect the coiled-coil domain and are probably all loss-of-dephosphorylation and gain-of-function, may somewhat differ from each other in terms of their functional impact. The genome-wide impact of these mutations on the transcriptome remains to be assessed in various cell types stimulated with a range of cytokines. In any case, the gain-of-function mutant *STAT1* alleles were dominant for GAF activation in all cell types tested. They affected cellular responses to various cytokines, including IFN-α/β, IFN-γ, and IL-27, which predominantly activate STAT1 over STAT3, and IL-6 and IL-21, which predominantly activate STAT3 over STAT1. These mutations probably also strengthen cellular responses to IFN-λ. However, they do not seem to affect STAT1-containing ISGF-3 activation by IFN-α/β, at least in the conditions tested. Moreover, STAT3 activation by IL-6, IL-21, IL-22, and IL-23 is maintained, suggesting that STAT3 activation by IL-26 is also intact.

The mutant *STAT1* alleles described herein enhance cellular responses to cytokines such as IFN-α/β, IFN-γ, and IL-27, which potently inhibit the development of IL-17--producing T cells via STAT1 ([@bib7]; [@bib70]; [@bib67]; [@bib4]; [@bib29]; [@bib39]; [@bib68]; [@bib18]; [@bib61]; [@bib19]; [@bib22]; [@bib26]; [@bib33]; [@bib69]; [@bib48]). These mutant alleles also increase cellular responses to IL-6 and IL-21, which normally induce IL-17--producing T cells via STAT3 rather than STAT1 ([@bib35]). Enhanced STAT1-dependent cellular responses to these two groups of cytokines probably impair the development of IL-17--producing T cells. It remains unclear whether this mechanism predominantly involves IL-17--inhibiting cytokines (IFN-α/β, IFN-γ, and IL-27), either individually or in combination. The available data from the mouse model suggest that IL-27 is the most potent of the three inhibitors. There is also evidence that these cytokines inhibit IL-17--producing T cell development in humans ([@bib61]; [@bib48]). Enhanced STAT1 and GAF activation in response to the IL-17 inducers IL-6 and IL-21, and perhaps IL-23, may also play a key role in disease, by antagonizing STAT3 responses. The effect of the aryl hydrocarbon receptor on IL-17 T cell development might also be enhanced by gain-of-function *STAT1* alleles ([@bib39]). Moreover, enhanced STAT1 activity downstream from IL-22 and IL-26 in cells, not detected in our study, might also contribute to the CMCD phenotype. Finally, thyroid autoimmunity in eight patients and systemic lupus erythematosus in another patient in our series probably resulted from the enhancement of IFN-α/β responses, as such autoimmunity is a frequent adverse effect of treatment with recombinant IFN-α or IFN-β ([@bib56]; [@bib64]). Importantly, no autoantibodies against IL-17A, IL-17F, or IL-22 were detected in the patients' serum ([Table I](#tbl1){ref-type="table"} and unpublished data).

Remarkably, germline mutations in human *STAT1* underlie susceptibility to three different types of infectious disease: mycobacterial diseases, viral diseases, and CMC. Patients bearing *STAT1* mutations and displaying mycobacterial and/or viral disease do not suffer from CMC, and the patients with CMCD caused by other *STAT1* alleles described here present no mycobacterial or viral disease. The pathogenic mechanisms involved are clearly different, with loss-of-function mutations in *STAT1* underlying mycobacterial and viral diseases ([@bib24], [@bib25]; [@bib15], Chapgier et al., b2009; [@bib43]; [@bib6]; [@bib44]). Human AR STAT1 deficiency impairs cellular responses to IFN-α/β, IFN-γ, IFN-λ, and IL-27 ([@bib25]; [@bib15], Chapgier et al., b2009; [@bib43]; [@bib44]). Viral diseases probably result from impaired IFN-α/β and, perhaps, IFN-λ immunity, although impaired IFN-γ and IL-27 immunity may also contribute to the phenotype. Patients with AD MSMD, heterozygous for loss-of-function dominant-negative mutations of *STAT1,* suffer from mycobacterial disease caused by the impairment of IFN-γ immunity ([@bib14]; [@bib24]). Overall, mutations impairing STAT1 function confer AD or AR susceptibility to intracellular agents, through the impairment of IFN-α/β (viral diseases) and/or IFN-γ immunity (mycobacterial diseases). In contrast, the gain-of-function *STAT1* mutations reported here confer AD CMCD because of the enhancement of STAT1-mediated cellular responses to STAT1-dependent repressors and STAT3-dependent inducers of IL-17--producing T cells. These studies neatly demonstrate that severe infectious diseases in otherwise healthy patients may be subject to genetic determinism ([@bib12], [@bib13]; [@bib2], [@bib3]). They also highlight the profoundly different effects that germline mutations in the same human gene may have, resulting in different infectious diseases through different molecular and cellular mechanisms.

MATERIALS AND METHODS
=====================

Massively parallel sequencing
-----------------------------

DNA (3 µg) extracted from EBV-B cells from the patient was sheared with a S2 Ultrasonicator (Covaris). An adapter-ligated library was prepared with the Paired-End Genomic DNA Sample Prep kit (Illumina). The SureSelect Human All Exon kit (Agilent Technologies) was then used for exome capture. Single-end sequencing was performed on a Genome Analyzer IIx (Illumina), generating 72-base reads.

Sequence alignment, variant calling, and annotation
---------------------------------------------------

BWA aligner ([@bib46]) was used to align the sequences obtained with the human genome reference sequence (hg18 build). Downstream processing was performed with the Genome analysis toolkit (GATK; [@bib50]), SAMtools ([@bib46]), and Picard Tools (<http://picard.sourceforge.net>). Substitution calls were made with a GATK UnifiedGenotyper, whereas indel calls were made with a GATK IndelGenotyperV2. All calls with a read coverage ≤2x and a Phred-scaled SNP quality of ≤20 were filtered out. All the variants were annotated with annotation software that was developed in-house. The data were further analyzed with sequence analysis software that had been developed in-house (SQL database query--driven system).

Molecular genetics
------------------

EBV-B cells and the STAT1-deficient cell line U3C were cultured as previously described ([@bib14]). Primary fibroblasts were cultured in DME supplemented with 10% fetal calf serum. Cells were stimulated with the indicated doses (in IU/ml or ng/ml) of IFN-γ (Imukin; Boehringer Ingelheim), IFN-α2b (IntronA; Schering-Plough), IL-27 (R&D Systems), IL-21 (R&D Systems), IL-22 (R&D Systems), IL-23 (R&D Systems), and IL-6 (R&D Systems). Genomic DNA and total RNA were extracted from cell lines and fresh blood cells, as previously described ([@bib14]). Genomic DNA was amplified with specific primers encompassing exons 6--10 of *STAT1* (available upon request), sequenced with the Big Dye Terminator cycle sequencing kit (Applied Biosystems), and analyzed on an ABI Prism 3730 (Applied Biosystems). We used the various alleles of *STAT1* in the pcDNA3 *STAT1*-V5 vector ([@bib14]; [@bib43]). We generated the various *STAT1* mutations by site-directed mutagenesis (QuikChange Site-Directed Mutagenesis kit; Stratagene) with the mismatched primers listed in [Table S4](http://www.jem.org/cgi/content/full/jem.20110958/DC1). U3C cells were harvested by trypsin treatment 24 h before transfection and replated at a density of 2.5 × 10^5^ cells/ml in 6-well plates. Plasmid DNA (5 µg per plate) carrying the WT or all the various mutant *STAT1* alleles was used for cell transfection with the Calcium Phosphate Transfection kit (Invitrogen).

Luciferase reporter assay
-------------------------

U3C cells were dispensed into 96-well plates (1 × 10^4^/well) and transfected with reporter plasmids (Cignal GAS and ISRE Reporter Assay kit; SABiosciences) and plasmids carrying the various alleles of *STAT1* or a mock vector, in the presence of Lipofectamine LTX (Invitrogen). 6 h after transfection, the cells were transferred back into medium containing 10% FBS and cultured for 24 h. The transfectants were then stimulated with IFN-γ (500 and 1,000 IU/ml), IL-27 (20 and 100 ng/ml), and IFN-α (500, 1,000, and 5,000 IU/ml) for 16 h and subjected to luciferase assays with the Dual-Glo luciferase assay system (Promega). Experiments were performed in triplicate and firefly luciferase activity was normalized with respect to *Renilla* luciferase activity. The data are expressed as fold induction with respect to nonstimulated cells.

Immunoblot analysis and electrophoretic mobility shift assays
-------------------------------------------------------------

The following optimal stimulation conditions were used. EBV-B or U3C cells were stimulated by incubation for 20 min with 100 µg/ml IL-21 or 25 ng of IL-22; 30 min with 10^3^ or 10^5^ IU/ml IFN-γ and IFN-α; 15 min with 50 ng/ml IL-6; or 30 min with 50 or 100 ng/ml IL-27. WB was performed as previously described ([@bib25]). In brief, cell activation was blocked with cold 1X PBS, cells were lysed in 1% NP-40 lysis buffer, and the proteins were recovered and subjected to SDS-PAGE. We used antibodies directed against phosphorylated STAT1 (pY701; BD), STAT1 (C-24; Santa Cruz Biotechnology), V5 (Invitrogen), α-tubulin (Santa Cruz Biotechnology), phosphorylated STAT3 (Cell Signaling Technology), lamin B1 (Santa Cruz Biotechnology), GAPDH (Santa Cruz Biotechnology), and STAT3 (Santa Cruz Biotechnology). EMSA was performed as previously described ([@bib14]). In brief, cell activation was blocked by incubation with cold 1X PBS, and the cells were gently lysed to remove cytoplasmic proteins while keeping the nucleus intact. We then added nuclear lysis buffer and recovered the nuclear proteins, which were subjected to nondenaturing electrophoresis with radiolabeled GAS (from the FCγR1 promoter: 5′-ATGTATTTCCCAGAAA-3′) and ISRE (from the ISG15 promoter: 5′-GATCGGGAAAGGGAAACCGAAACTGAA-3′) probes.

Staurosporine and pervanadate treatment of cells
------------------------------------------------

We assessed dephosphorylation by stimulating U3C transfectants with 10^5^ IU/ml IFN-γ. The cells were then washed and incubated with 1 µM staurosporine in DME for 15, 30, or 60 min. The cells were then lysed with 1% NP-40 lysis buffer, and the proteins recovered were subjected to immunoblot analysis.

Pervanadate was prepared by mixing orthovanadate with H~2~O~2~ for 15 min at 22°C. U3C transfectants were treated with pervanadate (0.8 mM orthovanadate and 0.2 mM H~2~O~2~) 5 min before stimulation. They were then stimulated with IFN-γ for 20 min. The stimulation was stopped by adding cold 1X PBS. The proteins were recovered and subjected to immunoblot analysis.

Extraction of nuclear and cytoplasmic proteins
----------------------------------------------

U3C transfectants or EBV-B cells were stimulated with IFN-γ or IFN-α for 20 min and subjected to nuclear and cytoplasmic protein extraction with NE-PER Nuclear and Cytoplasmic Extraction Regents (Thermo Fisher Scientific) according to the manufacturer's protocol.

Immunofluorescence staining
---------------------------

Immunofluorescence experiments were performed as previously described ([@bib14]). In brief, cells (transfected U3C or SV-40 fibroblasts) were stimulated for the times indicated with 10,000 IU/ml of IFN-γ. Cells were then washed with cold PBS and fixed with 4% PFA. The cells were washed and incubated with an antibody against STAT1, which was then detected by incubation with an Alexa Fluor 488--conjugated anti--mouse antibody.

T cell blast differentiation and stimulation
--------------------------------------------

PBMCs were recovered by centrifuging blood samples on Ficoll gradients, as previously described ([@bib14]). They were then cultivated, at a density of 1 million cells per ml in RPMI supplemented with 10% fetal calf serum and stimulated with phytohemagglutinin (1 µg/ml) for 3 d. Cells were then recovered, centrifuged on a Ficoll gradient, cultivated (at a density of 0.2 million cells/ml) to Panserin 401 supplemented with 10% FCS and glutamine 1X, and stimulated with 40 IU/ml IL-2 (Roche). Cells were then incubated for 30 min with 100 ng/ml IL-23. Activation was stopped by adding 1X cold PBS, and cells were processed for immunoblot analysis.

Modeling
--------

Images of the three-dimensional structure of STAT1 ([@bib17]) were generated with the 2002 PyMOL Molecular Graphics System (DeLano Scientific), using PDB accession no. [1BF5](1BF5).

Whole-blood assay of the IL-12--IFN-γ circuit
---------------------------------------------

Whole-blood assays were performed as previously described ([@bib28]). Heparin-treated blood samples from healthy controls and patients were stimulated in vitro with live *Mycobacterium bovis* BCG (Pasteur) alone or with IFN-γ (5,000 IU/ml; Boehringer Ingelheim). Supernatants were collected after 48 h of stimulation, and ELISA were performed with specific antibodies directed against IL-12p40 or IL-12p70, using kits from R&D Systems according to the manufacturer's instructions.

Production of IL-17A, IL-17F, and IL-22 by leukocytes
-----------------------------------------------------

### Cell activation.

IL-17A-- and IL-22--producing T cells were evaluated by intracellular staining or by ELISA, as previously described ([@bib20]). In brief, PBMCs were purified by centrifugation on a gradient (Ficoll-Paque PLUS; GE Healthcare) and resuspended in RPMI supplemented with 10% FBS (RPMI/10% FBS; Invitrogen). Adherent monocytes were removed from the PBMC preparation by incubation for 2 h at 37°C, under an atmosphere containing 5% CO~2~.

For ex vivo evaluation of IL-17-- and IL-22--producing T cells by flow cytometry, we resuspended 5 × 10^6^ nonadherent cells in 5 ml RPMI/10% FBS in 25 cm^2^ flasks and stimulated them by incubation with 40 ng/ml PMA (Sigma-Aldrich) and 10^−5^ M ionomycin (Sigma-Aldrich) in the presence of a secretion inhibitor (1 µl/ml GolgiPlug; BD) for 12 h.

For evaluation of the IL-17-- and IL-22--producing T cell blasts after in vitro differentiation, the nonadherent PBMCs were dispensed into 24-well plates at a density of 2.5 × 10^6^ cells/ml in RPMI/10% FBS and activated with 2 µg/ml of an antibody directed against CD3 (Orthoclone OKT3; Janssen-Cilag) alone, or together with 5 ng/ml TGF-β1 (240-B; R&D Systems), 20 ng/ml IL-23 (1290-IL; R&D Systems), 50 ng/ml IL-6 (206-IL; R&D Systems), 10 ng/ml IL-1β (201-LB; R&D Systems), or combinations of these four cytokines. After 3 d, the cells were restimulated in the same activation conditions, except that the anti-CD3 antibody was replaced with 40 IU/ml IL-2 (Proleukin i.v.; Chiron). We added 1 ml of the appropriate medium, resuspended the cells by gentle pipetting, and then split the cell suspension from each well into two. Flow cytometry was performed on one of the duplicated wells 2 d later, after stimulation by incubation for 12 h with 40 ng/ml PMA and 10^−5^ M ionomycin in the presence of 1 µl/ml GolgiPlug. FACS analysis was performed as described in the following section. The other duplicated well was split into two, with one half left unstimulated and the other stimulated by incubation with 40 ng/ml PMA and 10^−5^ M ionomycin for another 2 d. Supernatants were collected after 48 h of incubation, for ELISA.

### Flow cytometry.

Cells were washed in cold PBS, and surface labeling was achieved by incubating the cells with PECy5-conjugated anti--human CD3 antibody (BD) in PBS/2% FBS for 20 min on ice. Cells were then washed twice with 2% FBS in cold PBS, fixed by incubation with 100 µl of BD Cytofix for 30 min on ice, and washed twice with BD Cytoperm (Cytofix/Cytoperm Plus, fixation/permeabilization kit; BD). Cells were then incubated for 1 h on ice with Alexa Fluor 488--conjugated anti--human IL-17A (53--7179-42; eBioscience), PE-conjugated anti--human IL-22 (IC7821P; R&D Systems), or PE-conjugated anti--human IFN-γ (IC285P; R&D Systems) antibodies, washed twice with Cytoperm, and analyzed with a FACSCanto II system (BD).

### ELISA.

IL-17A, IL-17F, and IL-22 levels were determined by ELISA on the supernatants harvested after 48 h of whole-blood stimulation with 40 ng/ml PMA and 10^−5^ M ionomycin, or after in vitro PHA blast differentiation and 48 h of stimulation with 40 ng/ml PMA and 10^−5^ M ionomycin. We used anti--human IL-17A and anti--human IL-22 Duoset kits (R&D Systems) and the anti--human IL-17F ELISA Ready-SET-GO! set (eBioscience).

### Statistical analysis.

We assessed differences between controls, MSMD patients bearing loss-of-function *STAT1* alleles, and CMCD patients bearing gain-of-function *STAT1* alleles in terms of the percentages of IL-17A-- and IL-22--producing T cells, as assessed by flow cytometry, and in terms of the amounts of IL-17A, IL-17F, and IL-22 produced in various stimulation conditions, as assessed by ELISA. We used the nonparametric Wilcoxon test, as implemented in the PROC NPAR1WAY of the SAS software version 9.1 (SAS Institute). For all analyses, P \< 0.05 was considered statistically significant.

Online supplemental material
----------------------------

Fig. S1 shows that STAT1-CMCD mutants are gain-of-function alleles by loss of nuclear dephosphorylation. Fig. S2 is a schematic representation of the cytokines and transcription factors directing the development of naive CD4 cells into IL-17--producing T cells. Fig. S3 shows the normal response of CMCD patient cells to IFN-α in terms of ISGF3 activation, to IFN-γ in terms of STAT1 nuclear translocation; and to IL-23 and IL-22 in terms of pSTAT3. Fig. S4 shows impaired in vitro differntiation of IL-17-- and Il-22--producing T cell blasts in patients with CMCD and gain-of-function SATA1 mustations. Table S1 shows novel coding heterozygous variants found by whole-exome sequencing in the 6 different patients. Table S2 shows novel coding heterozygous variants found by whole-exome sequencing within genes shared by more than one patient. Table S3 lists conservation and predictions on the function of the mutant STAT1 alleles associated with CMCD. Table S4 lists the STAT1 GOF mutation created, and the pair of primers used. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20110958/DC1>.
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